Clinical trials: Insulin Resistance Syndrome X
Metabolic Syndrome X
Study In Patients With Dyslipidaemia
Study in patients with dyslipidaemia.
- Trial name
- NCT00264667
- Testing
- GW677954
- Where
- 50 sites in Argentina, Australia and 11 more
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Metabolic Syndrome X
Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease
The purpose of this study is the evaluation of the effects in obese patients with metabolic syndrome on the composition of the intestinal microbiota, markers of the syndrome (hypertension, dyslipidemia, inflammation biomarkers…
- Trial name
- PROSIR (NCT02972567)
- Testing
- Lactobacillus spp, Control
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Biosearch S.A.
Metabolic Syndrome X
ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome
The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a novel fermentation product of a freshwater algae ecosystem) vs.
- Trial name
- NCT00489333
- Testing
- ProAlgaZyme
- Where
- Cameroon
- Volunteers
- 52 people
- Sponsor
- Health Enhancement Products, Inc.
Metabolic Syndrome x
PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome
The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.
- Trial name
- NCT00296803
- Testing
- clopidogrel
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hypertension, Metabolic Syndrome X
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
- Trial name
- NCT00613314
- Where
- 122 sites in Philippines
- Volunteers
- 15,268 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Metabolic Syndrome X
A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabolic syndrome treated with either…
- Trial name
- NCT00675857
- Testing
- NC-503 (eprodisate disodium)
- Where
- 21 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Bellus Health Inc. - a GSK company
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Metabolic Syndrome X
Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults
The traditional risk factors for obesity are inappropriate diet, lack of exercise and genetic factors. However, recent observations have involved gut microbiota profiles as having an additional influence.
- Trial name
- NCT01004120
- Testing
- Bimuno, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Clasado
Insulin Resistance - Type A, Insulin Resistance - Type B
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-02 (NCT04221152)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Diabetes Mellitus, Type 2
Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
The study investigated the effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes.
- Trial name
- NCT00306644
- Testing
- Rosiglitazone
- Where
- Sweden
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Overweight, Metabolic Syndrome X
Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs
A randomized, double-blind, placebo controlled, parallel study to determine if Chromium (Cr), Phyllanthus emblica (PE) and Shilajit (SJ) supplementation and Phyllanthus emblica fruit extract supplementation promotes greater…
- Trial name
- NCT06641596
- Testing
- Cr-400, Cr-800, PE-500
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Kerry Group P.L.C
Hypertension, Metabolic Syndrome X
The Effects of Cilnidipine on Metabolic Syndrome Improvement
Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance.
- Trial name
- NCT00325936
- Testing
- Cilnidipine
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Metabolic X Syndrome Dyslipidemia
MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)
This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.
- Trial name
- NCT00703690
- Testing
- MK0767, Comparator: fenofibrate
- Volunteers
- 436 people
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Resistance - Type A, Insulin Resistance - Type B
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-01 (NCT04018365)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Overweight, Metabolic Syndrome X
Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overweight Adult Men
The purpose of this study was to determine the effects of NUTRIOSE® supplementation on body composition, satiety, and determinants of metabolic syndrome in overweight men.
- Trial name
- NCT01044680
- Testing
- NUTRIOSE
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Roquette Freres
Metabolic Syndrome X, Fatty Liver
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by…
- Conditions
- Metabolic Syndrome X, Fatty Liver, MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- Trial name
- ACOUSTIQ (NCT06661655)
- Testing
- Liver ultrasound
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- E-Scopics
Metabolic Syndrome X
ROMEO (Rosuvastatin in Metabolic syndrOme)
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
- Trial name
- NCT00395486
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 3 sites in South Korea
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Metabolic Syndrome, Type 2 Diabetes
LUPS-Lipids and Glucose Under Prospective Surveillance
Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes
- Trial name
- LUPS (NCT01313156)
- Where
- 2 sites in Germany
- Volunteers
- 1,962 people, healthy volunteers welcome
- Sponsor
- Asklepios proresearch